ISRG

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+2.06%

Status

scored

ISRG receives an Overweight rating with a disciplined 50% initial position in a single decisive tranche, entry at $405-410, hard closing-price stop at $383 (2x ATR below 50 SMA), and a structured three-phase scaling plan: 50% now, scale to 75% on confirmed post-Q3 beat-and-raise with 200 SMA reclaim, and final 25% on sustained breakout above $480. The Q3'26 print serves as a forced re-decision point, with trim discipline at $480-500 and $540-560 to lock in gains. This decision balances the confirmed fundamental inflection (+18.5% YoY revenue, 33.6% operating margin, $3.2B LTM FCF) against binary catalyst risk at 47.6x trailing P/E with unresolved quality-of-earnings flags (inventory +22% YoY, receivables +27% YoY).

Outcome

✓

Return

+0.21%

Status

scored

Trim 30-35% of ISRG exposure at current levels (~$414) to lock in the +26% bounce off the September $328 low and reduce beta-amplified binary event risk into late-October Q3 earnings. The Underweight rating captures the asymmetric risk/reward—where the bear case requires only one catalyst to break while the bull case demands multiple positives aligning—while preserving 65-70% of the position to participate in any post-print rally and maintaining the fortress balance sheet floor at $328.

Outcome

✓

Return

+2.41%

Status

scored

Initiate Overweight on ISRG via a 35/35/30 three-tier scale-in architecture with T1 at 35% deployed on confirmation (close >$400 with volume or dip to $392-400 zone), T2 at 35% on pullback to 50 SMA ($385-392) if the 50 SMA holds on close, and T3 at 30% on deep pullback to $365-372; hard stop at $360 weekly close, with mandatory 25-33% trim into Q3 FY2026 earnings (late October) to neutralize binary risk and a put spread hedge at $370/$320 (75-90 DTE) sized at 5% of position.

Outcome

✓

Return

-0.42%

Status

scored

Underweight rating maintained with a two-tranche execution strategy: trim 30-35% of ISRG exposure immediately at $405-410 to lock in the 24% bounce off the July low, then add a contingent 10-15% trim if price retests the $420-428 upper Bollinger Band zone within 5-7 days. A hard stop at $378 close (below 50 SMA, ~2x ATR) protects the residual position. Total exposure reduction targets 40-50% of original position ahead of Q3 FY2026 earnings, with post-earnings re-evaluation based on three scenarios (bullish/in-line/bearish) and clear upgrade/downgrade criteria.

Outcome

✓

Return

+3.71%

Status

scored

The analyst recommends initiating an Overweight position with Tranche 1 at 25-30% of target at ~$392, using a $360 hard stop (not $370) given the 1.465-beta name with an imminent binary event. A 5-10% put spread hedge ($370/$320, 75-90 DTE) is mandatory due to Q3 FY2026 earnings catalyst and Iran-inflation tail risk; T2/T3 entries are conditioned on closes above $414/$447 with volume confirmations.

Outcome

✗

Return

-2.32%

Status

scored

Maintain ISRG at Hold with tiered deployment architecture for new capital—1/3 position on confirmed close above $410 with volume >2M, 1/3 on test of $378-386 zone with MACD>0 and RSI>50, final 1/3 on confirmed breakout above $426 on volume ≥1.5× average. The Q3 FY2026 earnings (mid-to-late October) is the hard-dated forced re-decision point that will resolve the binary catalyst on 2027 per-procedure pricing for ~75% of recurring revenue. Hard stop at $378 (50 SMA), structural invalidation on weekly close below $355, with 5-7% tactical add if price bands in $395-$415 for >10 sessions without hitting a trigger.

Outcome

✓

Return

-1.33%

Status

scored

Maintain HOLD rating on ISRG as the trade-in acceleration versus U.S. procedure growth deceleration data remains ambiguous and cannot justify either a Buy or Underweight rating; scale-in 15-20% on pullback to $377-385 with MACD>0/RSI>50 confirmation, add 10% on capitulation flush below $365, and trim 20-25% at $480+ first test; hard stop at weekly close below $355 with Q3 FY2026 earnings in late October as mandatory binary catalyst forcing re-decision.

Outcome

✓

Return

-1.35%

Status

scored

Maintain an Underweight rating on ISRG with a recommended 20-25% trim of existing exposure in the $410-415 zone, reducing portfolio allocation from 3.5% to approximately 2.5-2.8%. The positioning sits within the 70-75% benchmark retention operating window, respecting both the 9/28 lesson against overcommitting near resistance and the 9/21 lesson that 75-80% retention produces negligible alpha. Macro headwinds (30-year Treasury at 2002 highs, mortgage rates near 7.58%) and ISRG's 47x P/E in the top decile of its 10-year range justify the Underweight, while improved technicals (MACD cross from 9/14, RSI 67, ATR compressing 17→11) and Q2 revenue reacceleration (+4.4% QoQ) prevent a more aggressive trim. The stop loss anchors to the 50 SMA at $376, not $350, with re-engagement requiring 200 SMA reclaim at $449 on volume ≥2.5M shares held 5+ sessions. Q3 FY2026 earnings (late October) serves as the hard-dated binary catalyst for forced re-evaluation.

Outcome

–

Return

-0.63%

Status

scored

Reduce ISRG by 25-30% into the $414-418 resistance zone to achieve a meaningful underweight (70-75% benchmark) versus the constrained 75-80% that produced +0.1% alpha on 9/21. The 14-session RSI at 69.59, Bollinger upper band touch at $417.51, and decelerating MACD histogram indicate an exhausted momentum setup sitting in the 2-year failed breakout zone of $415-450. Hedge the residual position with covered calls on 30% of residual (30-45 DTE, $430-440 strikes) plus 3-month $400 puts on 50% of residual (~3% position cost), with Q3 FY2026 earnings (late October) serving as the hard-dated binary catalyst forcing re-evaluation.

Outcome

✗

Return

+2.37%

Status

scored

Maintain ISRG at HOLD with a $440 price target and $348 stop-loss. Current setup shows a 10.1% discount to the 200 SMA at $450.90, with the recent +15.7% rally stalling at upper Bollinger Band ($411.92) on declining volume—counter-trend bounce, not reversal. Add triggers require either confirmed close above $450.90 on 1.5× average volume, retest/hold at ~$350 with bullish divergence plus stabilizing macro (10Y below 4.5%), or dovish Fed regime shift; trim 10-15% into $405-412 resistance if overweight; Q3 FY2026 earnings (late October) is the hard-dated forced re-decision catalyst.

Outcome

✓

Return

+1.42%

Status

scored

ISRG maintains HOLD rating with no new position initiation at $399, as the aggressive Buy case is disqualified by regime-mismatched targets and poor risk/reward configuration, while Underweight is mechanically blocked by prior reflection discipline. The decision is anchored to Q3 2026 earnings (late October) as the mandatory binary catalyst, with a trigger architecture allowing 25-33% starter sizing on pullback, breakout, or fundamental triggers rather than full commitment at current levels.

Outcome

✓

Return

+0.31%

Status

scored

Maintain ISRG at Hold with the Neutral analyst's volume-confirmed breakout framework; upgrade to Overweight (+100bp) only on a confirmed close above $410 on volume exceeding 2.5M shares, while maintaining a protective stop at the 50 SMA ($373) and hard-invalidating below $347 with conviction. The Q3 2026 earnings print (late October) is the mandatory binary catalyst requiring a forced re-decision regardless of outcome, with bullish scenarios (any two of: inventory/AR divergence narrowing, Ion procedure reacceleration, guidance reaffirmation) warranting upgrade to target $440, and bearish scenarios (any two of: divergence widening, Ion deceleration, downward guidance) warranting meaningful underweight with 50% trim.

Outcome

✓

Return

-0.94%

Status

scored

Maintain ISRG at HOLD as the rating that survives all binding constraints; the 9/21 reflection eliminates Underweight (20-25% trims produce zero alpha on quality compounders), while the 200 SMA at $453 uncrossed and unquantified 2027 ASP concession disqualify Overweight initiation. Two explicit add triggers are defined: Tier 1 at $385-$395 on constructive pullback (RSI >40, volume >2M, 50 SMA flattening) and Tier 2 at $413 confirmed daily close with volume >2M; stop anchored at $370 with Q3 2026 earnings as the hard-dated binary catalyst.

Outcome

–

Return

+0.11%

Status

scored

Maintain Underweight on ISRG with a calibrated trim to 75-80% of benchmark healthcare allocation (not the Aggressive's 50% or Conservative's 30-35%), executed in 2-3 tranches over 5-10 sessions. The Q3 2026 earnings (late October) is the mandatory binary catalyst that will trigger either upgrade to Overweight (target $440) or downgrade to Sell. The $372 stop (just below 50 SMA at $373) serves as technical invalidation, while the 9/18 reflection's explicit guidance to "retain more than 75% benchmark exposure" on quality names with momentum breakouts caps the trim magnitude.

Outcome

✗

Return

+2.12%

Status

scored

Maintain Underweight rating as the trim zone ($400-410, now active at $405) is being executed to reduce to 75% benchmark weight; the momentum shift (MACD bullish cross, RSI recovery from 29 to 61, Bollinger breakout on 4.87M shares) is genuine but structural confirmation remains pending with 200 SMA at $455 uncrossed, 2027 ASP cut on ~75% of recurring revenue unquantified, and Q3 earnings binary catalyst ahead. Stop on remaining position is $365 daily close invalidation with next support at the $332-352 capitulation zone.

Outcome

✗

Return

+2.55%

Status

scored

The analysts unanimously recommend reducing ISRG to approximately 50% of benchmark weight (trimming 1-2% of portfolio NAV) given forward-looking concerns including a 2027 instrument pricing reset, mathematically flattered EPS growth, and confirmed bearish technical structure. Capital freed from the trim should be deployed into lower-correlation healthcare positions rather than held as cash, with re-entry requiring two of three confirmations: 200 SMA reclaim at $456 with volume, two consecutive quarters of US procedure reacceleration or China policy clarity, or forward P/E compression below 25x.

Outcome

–

Return

+0.33%

Status

scored

Initiate ISRG at Overweight with a tiered entry starting at $390 (within Tier 1 zone $385-395) at 0.25-0.375% portfolio weight, scaling in at $370-380 and $345-355 on pullbacks, targeting 1.0-1.5% total position; hard stop at $338 below the July capitulation low provides structural invalidation if the basing thesis fails. Q3 earnings in October serves as a hard-dated binary catalyst—any two of inventory/revenue divergence narrowing, Ion reacceleration, or guidance reaffirmation triggers upgrade posture, while divergence widening or guidance cut forces downgrade to Hold/Underweight; 12-24 month structural re-rating requires reclaiming the 200 SMA at $456.

Outcome

✓

Return

+1.36%

Status

scored

Hold is the correct synthesis: fortress balance sheet ($5.2B cash, zero debt, 33.6% operating margin, 69% FCF growth) fully justifies maintaining existing exposure, but three unresolved headwinds—macro tightening (10y at 5%+, 94% no-cut probability), operational yellow flags (receivables +27.3% outpacing revenue +18.5%, U.S. procedure deceleration), and technical structure (price 80 points below declining 200 SMA, death cross forming)—argue against accumulation. The tiered Overweight framework initiated 9/8 produced +5.5% to +8.3% initial alpha but has stalled with Tier 3 ($378.87 50 SMA reclaim) never triggering; Q3'26 earnings is the mandatory binary catalyst with mid-November 2026 forced re-decision deadline.

Outcome

–

Return

-0.21%

Status

scored

Maintain tiered Overweight on ISRG, rejecting Research Manager Underweight and Trader Sell as structurally identical pre-committed trim programs explicitly forbidden by the 9/1 binding reflection for names 37% off highs with intact quality. Tier 1 (active at $350) and Tier 2 (active ~$360-365) remain in force with $315 hard stop; Tier 3 not triggered pending two consecutive closes above $378.87 with 50 SMA flattening. Hedge via 3-6 month $320-$340 protective puts (covered calls explicitly forbidden). Q3 2026 earnings (~6-8 weeks) is the mandatory binary catalyst; mid-November 2026 forced re-decision deadline per 9/3 reflection.

Outcome

✓

Return

+2.38%

Status

scored

The analyst overrides the Research Manager's Underweight and Trader's Sell recommendation, both classified as pre-committed trim programs explicitly forbidden by the binding 9/1 reflection on intact quality names 37.6% off highs with $8.6B net cash, +26.5% Q2 EPS growth, and $948M FCF. The tiered Overweight framework initiated 9/8 at $350 has produced +5.5% cumulative alpha over three sessions, Tier 2 has now fired at the $358 trigger, and the framework remains active with a $315 hard stop and protective puts ($320-$340) protecting against the technical breakdown risk the Aggressive Analyst identifies, pending Q3 2026 earnings (~6-8 weeks) as the mandatory binary catalyst.

Outcome

✓

Return

+2.41%

Status

scored

Maintain the tiered Overweight framework with trader's BUY at $360 as a 1.2% starter position, validated by recent +1.3% and +2.6% alpha outcomes. Use $343 initial stop and $315 structural hard stop; require two consecutive closes above $378 with ≥2.5M volume for Tier 2 scaling. Cap maximum combined exposure at 3.5% of portfolio, with Q3 2026 earnings (~6-8 weeks) as mandatory binary catalyst and mid-November 2026 as forced re-decision deadline.

Outcome

✓

Return

+2.04%

Status

scored

The Portfolio Manager maintains an OVERWEIGHT rating on ISRG at $350, overriding the Research Manager's Underweight and Trader's Sell, citing that both proposals represent the pre-committed trim architecture the 9/1 binding reflection explicitly forbids for names trading 42% off highs with intact quality metrics ($5.2B net cash, 28.4% net margin, 67.8% gross margin). The tiered framework (Tier 1 active at $350, Tiers 2-3 on confirmation) produced +1.3% alpha in its first session on 9/8, with a hard stop at $315 and mandatory re-decision tied to Q3 2026 earnings (~6–8 weeks) and a mid-November 2026 deadline.

Outcome

✓

Return

+0.88%

Status

scored

The Portfolio Manager overrides both the Research Manager's Underweight and the Trader's Sell to initiate a tiered Overweight on ISRG at current spot $350, based on the 9/4 ISRG reflection's binding constraint. The three-tranche architecture starts with 25–33% at $350 with a $315 hard stop, adds 25–33% on confirmation triggers (RSI divergence or volume climax at $328–356 retest, or close ≥$358), and completes with 33–40% only on confirmed daily close above $379 with flattening 50 SMA slope, with a mid-November 2026 forced re-decision deadline and Q3 2026 earnings as mandatory binary catalyst.

Outcome

✗

Return

-4.51%

Status

scored

Maintain ISRG at benchmark weight with no fresh capital deployment and no incremental trim; the rating collapses to Hold because both Buy/Overweight (disqualified by 9/2 lesson requiring MA reclaim/MACD cross before scaling) and Sell/Underweight (disqualified by 9/1 lesson on 35%-off-highs asymmetry) are vetoed by recent binding lessons. The Hold carries a hard-dated forced re-decision deadline of mid-November 2026 (Q3 earnings ~October is the binary catalyst), after which the framework must either upgrade on a fired technical trigger or downgrade/underweight reassessment if no trigger has fired and the stock remains below $381.

Outcome

✓

Return

-0.85%

Status

scored

Hold rating is maintained on ISRG as both directional alternatives are vetoed by binding lessons: Underweight/Sell are disqualified by the 9/1 lesson (38% off highs with intact fundamentals and active buyback demand), while Overweight is disqualified by the 9/2 lesson (price below all declining MAs with MACD at -3.11). No incremental trim or tiered add is warranted; hard stop sits at $328, with Q3 2026 earnings (~6 weeks) serving as the mandatory binary catalyst for re-engagement triggers.

Outcome

✗

Return

-0.55%

Status

scored

Shift to tiered Overweight accumulation targeting Intuitive Surgical at 38% off highs with elite fundamentals intact—Q2 2026 revenue +18.5%, 33.6% operating margin, $5.22B net cash, and $948M quarterly FCF with active buybacks. Add 25-33% of full position at $360-372 with a 2x ATR stop at $348; second tranche triggered on $382.93 reclaim with volume >2.2M shares or $332 retest with bullish RSI divergence. Q3 2026 earnings (~6-8 weeks) is the mandatory binary catalyst determining upgrade to Buy or downgrade.

Outcome

–

Return

+0.71%

Status

scored

ISRG Underweight rating reflects a binding constraint from consecutive Hold failures (8/13 -1.5%, 8/25 -0.4%, 8/28 -1.7%, 8/31 -1.3% alpha) demonstrating that pure retention in confirmed technical deterioration is structurally alpha-destructive; execute 35-40% trim in tranches (third at $369, third at $375, final third on 50 SMA retest at $383) targeting post-trim weight of 60-70% of benchmark, with $340 stop and $430-440 covered-call overlay per the 8/27 success template.

Outcome

✗

Return

-2.02%

Status

scored

Maintain ISRG at Hold with widened first trim trigger at $345 (below August swing low, ~2.7 ATRs cushion) to avoid noise-driven whipsaw in a basing pattern. The bull case requires four independent catalysts (estimates hold, technicals reverse, GLP-1 non-event, multiple confirmations) versus the bear case's simpler trend persistence — that asymmetry of required catalysts rules out aggressive adding into a franchise with fortress balance sheet ($5.2B cash, zero debt), record $1.06B Q2 OCF, and +150 bps gross margin expansion. Q3 2026 earnings in 6-8 weeks is the mandatory re-evaluation catalyst.

Outcome

✓

Return

+1.14%

Status

scored

ISRG remains Hold as the middle path between aggressive (coiled-spring bull) and conservative (bearish trim) analysts—fundamentals are elite (Q2 revenue +18.5% YoY, 33.6% operating margin, $948M FCF) but technicals stay bearish with hostile macro (88% no-cut probability). Execution architecture is mandatory: trim bands $395-425, early de-risk at $358 (lower Bollinger), hard stop $345, structural stop $328.57, and starter position only on confirmed $384 reclaim with MACD/RSI confirmation. Mandatory Q3 2026 earnings review (~6-8 weeks) and mid-November 2026 checkpoint force directional upgrade (Overweight if 50 SMA reclaims + growth >17%) or downgrade (Underweight with larger trim).

Outcome

✗

Return

+1.51%

Status

scored

Underweight ISRG with a 35-40% trim of current exposure (upper end of Research Manager's range per the binding 8/26 reflection lesson), executed in phased fashion between $370-378 while avoiding the $377-384 supply zone where rallies have been rejected twice. Target post-trim weight at 55-65% of benchmark (meaningful underweight, not full exit), with stop at $402-405 (above prior swing high at $401.27), put-spread insurance below $340, and covered-call overlay at $430-440 strike. Mandatory Q3 2026 earnings re-evaluation (~6-8 weeks) with default 10-15% additional trim if US procedure growth fails to reaccelerate AND DSO continues expanding.

Outcome

–

Return

-0.90%

Status

scored

Execute a 33-50% trim of ISRG exposure on rallies into the 50 SMA at $385.80, targeting a post-trim weight of 50-67% of benchmark; maintain the position with a hard structural stop at $328.57 and a 3-6 month put spread below $340 as tail-risk insurance, while re-evaluating decisively at Q3 2026 earnings (~6-8 weeks).

Outcome

✓

Return

-0.38%

Status

scored

ISRG maintains Hold at 85-90% benchmark weight with explicit trigger architecture to avoid the three consecutive negative-alpha Hold sessions (-1.5%, -0.7%, -0.2%). Maintain exposure given Q2's strong fundamentals (revenue +18.5% YoY, FCF +69% YoY to $948M, $5.2B net cash) and fortress balance sheet, while preparing downside trim to 75% benchmark if price closes below $328.57 on volume, as that failure signals next measured move to $290-300 zone.

Outcome

–

Return

-0.46%

Status

scored

ISRG warrants an Overweight rating based on Q2 2026 acceleration (revenue up 18.5%, EPS up 26.5%, 29.3% operating margin) and attractive forward PEG near 0.80, but the position should be entered in staged tranches rather than as a full commitment. Initiate only ~20% of target allocation near $370-$375, with the next tranche conditional on a $346-$360 retest producing a higher low or a volume-confirmed reclaim of the $387.51 50-day SMA and $402 resistance with positive MACD and RSI above 55.

Outcome

✓

Return

-1.38%

Status

scored

ISRG remains Underweight with a 15-20% trim of remaining exposure recommended at $385-400 rallies, scaled over 3-4 sessions, targeting 50-60% benchmark weight; covered calls at $430-440 strike to be executed at decision timestamp; stops set at $365-375 volatility-based, $332 structural, and $405-410 directional invalidation; mandatory Q3 2026 earnings re-evaluation with defined re-entry triggers at 50 SMA ($388) and 200 SMA ($473).

Outcome

–

Return

+1.16%

Status

scored

Underweight ISRG at $374 is maintained, rejecting both the Research Manager's Overweight and the trader's 50-75% Buy sizing. Trim 30-35% of ISRG exposure on rallies into $385-400, layered with a covered call overlay at $430-440 strike (3-6 month tenor) executed at decision timestamp. Position should be reduced to 65-70% of benchmark weight with tactical stop $365-375 and hard structural stop $332, with mandatory Q3 2026 earnings re-evaluation as the time-based trim trigger.

Outcome

✓

Return

-5.84%

Status

scored

Underweight ISRG with a calibrated 20-25% trim on rallies into $400-416, paired with an immediate covered-call overlay at $430-440 strike (3-6 month tenor) executed at decision timestamp; retain 70-80% of benchmark weight. The three consecutive prior ISRG Holds produced negative alpha (-1.5%, -0.7%, -0.2%) while the 8/18 Underweight template at the same level produced +1.5% alpha, making the bounded-participation template the binding constraint; Q3 2026 earnings (~6-8 weeks) serve as mandatory time-based re-evaluation trigger with default action to trim another 10-15% if U.S. procedure growth does not reaccelerate AND gross margin does not stabilize above 66%.

Outcome

✗

Return

+1.67%

Status

scored

ISRG Underweight rating with 20-25% trim on rallies into $400-416, retaining 70-80% benchmark weight while layering covered calls at $430-440 strike per the LIN collar lesson; volatility-based tactical stop at $365-375 replaces the trader's $475 structural stop, with hard floor at $332 July panic low. Mandatory Q3 2026 earnings re-evaluation (~6-8 weeks) is the time-based trim trigger, with default action to trim another 10-15% if procedure growth does not reaccelerate AND gross margin does not stabilize above 66%.

Outcome

–

Return

+0.22%

Status

scored

Adopt Overweight with 30% initial sizing (reduced from the trader's 40-50% to honor the 8/14 ISRG lesson), initiating at $390 limit with a hard stop at $325 and no discretion to widen. Pre-commit a September 12 time-based trim trigger to trim 50% if no close above $400-414 on above-average volume, addressing the 8/13 and 8/12 Hold failures. Scale-in 30% on sustained $400-414 reclaim with volume, and add the final 40% only on $476 200 SMA reclaim or Q3 2026 earnings confirmation.

Outcome

✗

Return

-1.06%

Status

scored

Initiate ISRG at 40-45% allocation at $401 with a $374 hard stop, scaling in 25% on a 10 EMA retest at $385-388 and final 15% only upon BOTH $432 reclaim AND 200 SMA retest at $477. Mid-September time-based trim trigger activates if $432 is not reclaimed; Q3 2026 earnings serve as the fundamental thesis test, targeting $478 with asymmetric 2.85-to-1 risk/reward.

Outcome

✓

Return

-1.68%

Status

scored

Maintain HOLD at $401, avoiding additions into overhead resistance at $477 200-SMA while maintaining current exposure. Key tactical entry trigger at $408.60 Bollinger upper band on volume confirmation warrants a 25-33% scale-in; failure to confirm within two weeks triggers a one-third trim. Hard stop at $365 on core position, tightened to $385 on any new tactical adds.

Outcome

✓

Return

0.00%

Status

scored

The consensus HOLD at ≤5% weight ($401.23 entry) layers the Neutral analyst's tactical refinements onto the trader's framework, maintaining the $332 hard stop but tightening to ~$374 breakeven if ISRG closes above the 50 SMA ($392) for three sessions. Key execution triggers include trimming one-third if price fails to close above $406 on volume within two weeks, and scaling in at $377-365 only if RSI holds above 40; upgrade/downgrade catalysts center on $420 weekly close confirmation and $365 breakdown respectively.

Outcome

–

Return

+0.01%

Status

scored

ISRG is rated Underweight with a $360 price target over 12-18 months. Reduce existing exposure by trimming 30-40% at current levels ($401) and any rally into $406.40 (upper Bollinger band), with an additional 25-30% trim into the $425-$435 resistance zone. Hold a core position sized at ≤50% of normal with a hard stop at $377.94 (10 EMA) — a break opens downside to $344.55 and the lower Bollinger band near $323. Do not initiate fresh longs until a confirmed close above $479.20 (200 SMA) on volume validates a structural reversal.

Outcome

✓

Return

+2.00%

Status

scored

Maintain ISRG at Hold with existing exposure generating +3.8% alpha, but do not initiate new capital at $393 due to structurally broken trend (18% below 200 SMA) and a forward P/E of ~32.6x that offers no valuation cushion—wait instead for confirmed close above $402 on above-average volume to enter a 1.0–1.5% starter position, scaling to full Buy only on $480 200 SMA reclaim with improving slope. Stop reference for new entries is $370–375, with exit triggered below $328 on volume.

Outcome

✓

Return

+3.85%

Status

scored

Maintain ISRG position at current sizing given the 23% drawdown on an accelerating compounder, but resist aggressive adding due to high beta (1.46) and overhead resistance from declining moving averages. Wait for a daily close above $393 on above-average volume before scaling in, with a mental stop near $340 and re-evaluation below the $328.57 panic low. Hold balances bull and bear arguments: preserve business exposure while respecting the tape signal that institutional repricing carries information.